PCI 7 November 2023, 15:22
Thermofisher: Thu 29 February 2024, 11:15
BMG Labtech: Wed 18 September 2024, 11:55
Owen Mumford 12 January 2022, 16:46

Current Edition

Cell and Gene Therapy

Upcoming Events

PEGS Boston – 17/02/2025
NextGen BioMed – 04/02/2025
BioTrinity 2025 – January 30th 2025
Elrig R&I 2025 – 27th January 2025
Biotechnology Show 2025: 20th January 2025
Anglonordic: 16th January 2025
AI in Drug Discovery – SAE media – January 14th 2025

Advertisement

Fujifilm rectangle: Fri 22 November 2024, 14:23
Roald Dahl Charity: Fri 15 November 2024, 12:57
A&M STABTEST: Fri 21 June 2024, 11:43
CDD Vault: Wed 17 July 2024, 11:46
Aurisco – 04/02/2025
Volume 4 Issue 3

Shoring up Diagnostics Manufacturing for the Next Pandemic

As the global response to COVID-19 continues to move from a state of national lockdowns to the re-opening of societies, diagnostic assay developers are confronting tw...
Continue Reading →
Volume 4 Issue 3

4 Drugs Facing Key Patent Expirations and Potential Generic Entry From September 2021–November 2021

A challenge in anticipating generic entry is elucidating which patents and regulatory protections constrain generic entry. Yali Friedman at DrugPatentWatch presents a...
Continue Reading →
Volume 4 Issue 3

Divided by a Common Language: PV Differences Between the UK and the US – Notes for Ambitious Biotechs

In the modern market, small and nimble biotechs possess many great advantages in terms of their ability to bring new innovation to market quickly, unhindered by legac...
Continue Reading →
Volume 4 Issue 3

Regulatory Challenges Associated with the Development of Cell and Gene Therapies

The development of safe and effective cell and gene therapies (CGTs) relies on regulatory compliance and critical selection and qualification of raw materials. Regula...
Continue Reading →
Volume 4 Issue 3

How to Bring Your Oncolytic Virus Innovation to Market: the Secret to Successful Development

Cancer continues to be a major burden on healthcare systems across the world, with global spending on therapies and supportive care drugs expected to reach $200 billi...
Continue Reading →
Volume 4 Issue 3

CRISPR-Cas9 Knockout Screening Using Primary Human Cells in Drug Discovery

While significant progress has been made carrying out CRISPR screens in immortalised cell lines, a more physiological and clinically relevant alternative is human pri...
Continue Reading →
Volume 4 Issue 3

Are We Nearly There Yet? The Ongoing Journey of CAR-T Cell Therapies

CAR-T cells have a genetically engineered T-cell receptor (TCR) that directs their binding to cancer cells. In first-generation CARs, the TCR was engineered to expres...
Continue Reading →
Volume 4 Issue 3

Viral Vector Engineering to Improve Clinical Performance and Accelerate Timeline to Success for Novel Gene Therapies

Viruses are known to be dangerous pathogens which invade host cells and hi-jack their cellular machinery to direct the replication and transcription of their own geno...
Continue Reading →
Volume 4 Issue 3

E&L Standards: Empowering Confident Labware Choices

All labware has some extractable and leachable content. It is important to recognize that extractables and leachables are two different things. Extractables are organ...
Continue Reading →
Volume 4 Issue 3

Residual Impurities in Biopharmaceutical Products

Process-related impurities or residual impurities are formed at any time during upstream or downstream processes. They are compounds that are present at very low conc...
Continue Reading →
Newcells 3 June 2024, 15:12
Novonordisk: Wed 17 July 2024, 11:22
FujiFilm 30 October 2023, 16:23
Autoscribe Mon 26 June 2023, 15:15
Aldevron: 16th January 2025
Richter: Wed 23 October 2024, 09:03
GenXPro: Mon 16 September 2024, 10:40